Impax/Teva Launch Wellbutrin SR Generic As Andrx Relinquishes Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
The 150 mg Impax/Teva product is following Eon's and Watson's 100 mg generics to the market. Andrx will receive a share of the profits.
You may also be interested in...
GSK Wellbutrin XL Has Captured Half Of Total Bupropion Market
Wellbutrin XL holds 49.6% share of new scripts written for Wellbutrin brand and generic equivalents, Biovail reports. Biovail revenues from product jump to $79.1 mil. in quarter, helped by move up to next tier of pricing in supply agreement with GSK.
GSK Wellbutrin XL Has Captured Half Of Total Bupropion Market
Wellbutrin XL holds 49.6% share of new scripts written for Wellbutrin brand and generic equivalents, Biovail reports. Biovail revenues from product jump to $79.1 mil. in quarter, helped by move up to next tier of pricing in supply agreement with GSK.
Zyban Generics Enter Market; Impax/Teva Launch After Andrx Surrenders Exclusivity
Andrx will share in the profits of Impax/Teva’s bupropion 150 mg for smoking cessation for six months. Relinquishment of first-to-file rights mirrors Andrx’ earlier decision to give up exclusivity on Wellbutrin SR.